Issues surrounding age: Vascular disease in the elderly

Current Opinion in Lipidology

Volumn 12, Issue 6, 2001, Pages 601-609

  Shepherd, James ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN; STATIN;

AGING; ARTHRITIS; COGNITION; COMORBIDITY; CORONARY ARTERY DISEASE; DEGENERATIVE DISEASE; DIABETES MELLITUS; ELDERLY CARE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEART DISEASE; HUMAN; INSULIN RESISTANCE; OXIDATION REDUCTION REACTION; PHYSICAL DISABILITY; PRIORITY JOURNAL; REVIEW; SOCIAL WORK; STRESS; STROKE; SURVIVAL; TREATMENT PLANNING; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; AGING; ANTILIPEMIC AGENTS; CHOLESTEROL; CLINICAL TRIALS; COGNITION; CORONARY ARTERIOSCLEROSIS; HUMANS; INSULIN RESISTANCE; MIDDLE AGED; OXIDATION-REDUCTION; TIME FACTORS; VASCULAR DISEASES;

EID: 0035200660     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200112000-00002     Document Type: Review

References (93)

1. Brain degeneration. Older and wiser
2. Serum cholesterol concentrations and all cause mortality in older people
3. Serum cholesterol, high-density lipoprotein cholesterol and five-year survival in elderly people
4. Serum cholesterol and 20-year mortality in black and white men and women aged 65 and older in the Evans County Heart Study
5. Serum lipid levels and the severity of coronary and cerebral atherosclerosis in adequately nourished men 60-69 years of age
6. Some cardiovascular risk markers are also important in old age
7. Cholesterol and mortality. 30 years of follow-up from the Framingham Study
8. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all cause mortality in persons older than 70 years
9. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly
10. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adults Treatment Panel III)
11. Effects of hormone replacement therapy on serum lipids in elderly women
12. Cardiovascular and atherogenic aspects of subclinical hypothyroidism
13. The aging thyroid. The use of thyroid hormone in older persons
14. Oestrogen and protection against cardiovascular disease: Potential versus reality
15. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
16. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease
17. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
18. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
20. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
21. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
22. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
23. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
24. Third Report of the National Cholesterol Education Program expert panel on detection, evaluation and treatment of high blood cholesterol in adults (ATPIII)
25. High density lipoprotein, total cholesterol screening and myocardial infarction. The Framingham Study
26. Genetic determinants of high density lipoprotein levels
27. High plasma insulin and lipids profile in older individuals: The Italian Longitudinal Study on Aging
28. Fasting plasma glucose in nondiabetic elderly women predicts increased all-causes mortality and coronary heart disease risk
29. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerotic vascular disease
30. Fasting blood glucose: An under-estimated risk factor for cardiovascular death. Results from a 22 year follow-up of healthy nondiabetic men
31. Pravastatin and the development of diabetes mellitus
32. Postprandial retinyl palmitate and squalene metabolism is age dependent
33. Left ventricular concentric remodelling rather than left ventricular hypertrophy is related to the insulin resistance syndrome in elderly men
34. Atherogenesis: A postprandial phenomenon
35. Postprandial lipemia, fenofibrate and coronary artery disease
36. Postprandial plasma retinyl ester response is greater in older subjects compared with younger subjects. Evidence for delayed plasma clearance of intestinal lipoproteins
37. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome
38. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
39. Aging induces left ventricular concentric remodelling in normotensive subjects
40. Atherogenic lipid profile in elderly patients with ischaemic cerebrovascular disease
41. Oxidative stress, caloric restriction and aging
42. Physical activity, aerobic capacity and selection markers of oxidative stress and the antioxidant defence system in healthy active elderly men
43. Vitamin E: Too much or not enough?
44. Age influence on the immune system
45. Age-associated changes in human T cell phenotype and function
46. Aging and immune function
47. Diminished calcium signal generation in subsets of T lymphocytes that predominate in old mice
48. Decline in immune function with age: Interaction with specific nutrient deficiencies
49. Reactive oxygen species and antioxidants in signal transduction and gene expression
50. Effect of in vitro generation of oxygen free radicals on T cell function in young and old rats
51. Glutathione augments in vitro proliferative responses of lymphocytes to Concanavalin A to a greater degree in old than in young rats
52. In vitro glutathione supplementation enhances interleukin-2 production and mitogenic response of peripheral blood mononuclear cells from young and old subjects
53. Dietary vitamin E and T cell-mediated function in the elderly: Effectiveness and mechanism of action
54. Vitamin E and Alzheimer Disease: The basis for additional clinical trials
55. Evidence of an oxidative challenge in the Alzheimer's brain
56. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's Disease
57. Cell biology of the β amyloid precursor protein and the genetics of Alzheimer's Disease
58. β-amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion
59. Hydrogen peroxide mediates amyloid beta protein toxicity
60. Secreted forms of β amyloid precursor protein protect hippocampal neurones against amyloid β peptide induced oxidative injury
61. Vitamin E protects nerve cells from amyloid β-protein toxicity
62. Chronic antioxidant treatment improves the cognitive performance of aged rats
63. Reversal of age-related increase in brain protein oxidation by chronic administration of N-tert-butyl-alpha-phenylnitrone
64. The underused miracle: The statin drugs are to atherosclerosis what penicillin was to infectious diseases
65. Pleiotropism among the statins
66. Relation of CRP and coronary heart disease in the MRFIT nested case-control study
67. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
68. D-dimer, CRP and risk of ischaemic heart disease: The Speedwell Study
69. CRP, sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle aged men
70. C reactive protein, cardiovascular risk factors and mortality in a prospective study in the elderly
71. C reactive protein is a strong but non specific risk factor of fatal strokes in elderly persons
72. Serum C reactive protein and self reported stroke
73. Effect of statins on c-reactive protein in patients with coronary artery disease
74. Long-term effects of pravastatin on plasma concentration of c-reactive protein
75. Measurement of c-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
76. Is hypercholesterolemia a risk factor and should it be treated in the elderly?
77. Elderly patients at risk for coronary heart disease or strokes: Selecting an ideal product for lipid lowering
78. The relationship between cholesterol and stroke
79. Decreased prevalence of Alzheimer Disease associated with HMG CoA reductase inhibitors
80. Statins and the risk of dementia
81. The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
82. Stimulation of bone formation in vitro and in rodents by statins
83. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent prenylation of G-proteins including RAS
84. Role of lipids in osteoporosis
85. HMG CoA reductase inhibitors increase bone mineral density in type 2 diabetes mellitus patients
86. HMG CoA reductase inhibitors and the risk of hip fractures in elderly patients
87. Inhibitors of HMG CoA reductase and risk of fracture among older women
88. Effect of pravastatin on frequency of fracture in the LIPID study